Shanghai MicuRx Pharmaceutical Co., Ltd. (SHA:688373)

China flag China · Delayed Price · Currency is CNY
6.25
+0.13 (2.12%)
Feb 3, 2026, 4:00 PM EST
31.86%
Market Cap4.10B +25.9%
Revenue (ttm)136.70M +13.9%
Net Income-342.96M
EPS-0.53
Shares Out656.23M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume6,116,238
Average Volume12,240,975
Open6.18
Previous Close6.12
Day's Range6.12 - 6.25
52-Week Range4.67 - 10.31
Beta0.77
RSI43.77
Earnings DateMar 28, 2026

About SHA:688373

Shanghai MicuRx Pharmaceutical Co., Ltd., a biopharmaceutical company, discovers, develops, and commercialize drugs for unmet medical needs. It is developing Contezolid (MRX-I) and Contezoilid acefosamil (MRX-4) oxazolidinone antibiotics for multidrug-resistant gram-positive bacteria; MRX-8 MRX, a polymyxin antibiotic, to target multidrug-resistant Gram-negative bacteria; MRX-5 for multidrug-resistant gram-negative bacteria; MRX-7 for multidrug-resistant gram-positive bacteria; MRX-15 and MRX-17 to treat kidney disease; MRX-18 for the treatment... [Read more]

Sector Healthcare
Founded 2007
Employees 177
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688373
Full Company Profile

Financial Performance

In 2024, SHA:688373's revenue was 130.27 million, an increase of 43.51% compared to the previous year's 90.78 million. Losses were -440.72 million, 4.65% more than in 2023.

Financial Statements